Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study.
Authors not listed
Norwegian University of Science and Technology · 2014
Abstract
The purpose of this study is to determine treatment effects in patients with retinal pigment epithelium detachment (PED) in relation to Age Related Maculopathy (AMD). Patients with newly diagnosed PED without choroidal neovascularisations (CNV), will be randomized to either treatment or observation. The treatment group will first be given injections with anti Vascular Endothelium Growth Factor (anti-VEGF). If the injections do not have any effect, Verteporfin Photodynamic Therapy (PDT) will be given. All patients will be followed for a period of 2 years. It is hypothesized that treatment stops the progression of the disease and stabilizes the vision in this subgroup of patients with AMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2014). Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study. <em>Norwegian University of Science and Technology</em>. https://clinicaltrials.gov/study/NCT01746875
Vancouver
Anonymous. Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study. Norwegian University of Science and Technology. 2014.
BibTeX
@misc{anon2014Pigmen,
title = {Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study.},
author = {Anonymous},
journal = {Norwegian University of Science and Technology},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Bayer 2016
Open access · US-GOV
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
University Health Network, Toronto 2014
Open access · US-GOV
Progression of Geographic Atrophy and Intravitreal Injections of Ranibizumab Among Treated for Age-related Macular Degeneration
Clinique de Retine de l'est 2025
Open access · US-GOV
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Sorlandet Hospital HF 2022
Open access · US-GOV
Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse
University Hospital, Lille 2023
Open access · US-GOV
A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma
Fondazione EMN Italy Onlus 2008
Open access · US-GOV